• search
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
News News



Aurigene Pharmaceutical Services Launches its New Branding at CPHI North America

Aurigene has been established as a wholly-owned subsidiary of Dr. Reddy’s through the merger of Aurigene Discovery Services and Dr. Reddy’s Custom Pharma Services (CPS). The launch of the brand happened during the pandemic and it is therefore the first opportunity for the team to exhibit the new brand to its customers.

Read More

Aurigene Pharmaceutical Services, Dr. Reddy's Laboratories and DNDi to explore joint opportunities to develop affordable and life-saving new drugs for Neglected Tropical Diseases

Potential partnership to explore new therapeutic solutions and serve unmet needs of patients in Neglected Tropical Diseases in LMICs and beyond.

Read More


DeepMatter to trial its DigitalGlassware® platform with Aurigene Pharmaceutical Services

DeepMatter Group Plc (AIM: DMTR, “Deepmatter”, the “Group”), the international digital chemistry data company, has signed a trials agreement with Aurigene Pharmaceutical Services Limited (“Aurigene Pharmaceutical Services”), based in Hyderabad, India, to supply its DigitalGlassware® platform.

Read More

Aurigene Pharmaceutical Services Limited (APSL) invests in adding Large Molecule Discovery and Development Services

Aurigene Pharmaceutical Services Limited, a wholly-owned subsidiary of Dr. Reddy’s expands its existing discovery and development capacities with the inauguration of a biotherapeutics discovery facility in Hyderabad, India.

Read More
Aurigene Pharmaceutical Services is

a leading CRO/CDMO

that provides contract research, development and manufacturing services

Contact Us


Pharmaceutical Services

Oligonucleotide as a novel class of therapeutic modality

JULY 02, 2021

Studies and Research

The influence of formulation development and its route of administration

JANUARY 04, 2021

Pharmaceutical Services

The Importance of Carbohydrate Synthesized Drugs

JANUARY 04, 2021

Early Phase development

Safety assessment


Technology meets sustainability - How a complex API development process goes green

Accelerating Drug Discovery Through Innovative Partnerships

Evolution in Pharma Industry and Demand for Integrated CDMO

Peptide Development and Manufacturing

Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.

Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry

Simple and efficient synthesis of imidazoquinoxalines and spiroquinoxalinones via pictect-spengler reaction using Wang resin, Synthetic Communications


You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.